Abstract:Cancer is one of the main causes of death in the world and thus a global public health problem. Among the treatments available for cancer are surgery, radiotherapy, and chemotherapy. Currently, there is increased interest in the combination of two or more antitumor agents to achieve a synergistic effect in cancer therapy. Doxorubicin (DOX), a chemotherapeutic which has a potent antineoplastic action, has been used in the treatment of various tumors. However, the use of DOX is limited, mainly due to the cardiotoxicity. Therefore, nanostructured systems, such as liposomes, have been developed to carry this drug and target the tumor region, since tumor tissues present enhanced permeability and retention for nanosystems. Cardiac glycosides, such as digitoxin, have recently shown great antitumor potential despite the low therapeutic index which may limit their use. Furthermore, some compounds of this class have low water solubility, which makes their in vivo administration difficult. In this context, liposomes represent a valid strategy to carry simultaneously antitumor drugs allowing their intravenous administration. In this study, liposomes loaded with glucoevatromonoside containing peracetylated glucose hydroxyl groups (GEVPG) and DOX at molar ratio of 1:1 (SpHL-GEVPG:DOX 1:1) were developed, and their chemical and physicochemical properties were evaluated. This formulation presented a combination index (CI) lower than 1 at inhibitory concentration of 90 % growth (IC90) for three human breast tumor lines evaluated (0.52 ± 0.39 for MDA-MB-231, 0.19 ± 0.13 for MCF-7, and 0.99 ± 0.09 for SKBR-3). These results indicate a synergistic cytotoxic effect of the GEVPG and DOX combination encapsulated in liposomes. In addition, SpHL-GEVPG:DOX 1:1 presented selectivity towards these cancer cells. Long-term in vitro cytotoxicity studies demonstrated that MDA-MB-231 surviving cells after treatment with SpHL-GEVPG:DOX 1:1 did not recover proliferation capacity after 21 d. From the studies of cell cycle and death pathway evaluation, it was observed that SpHL-GEVPG:DOX 1:1 arrested the cell cycle in the G2/M phase and similarly induced apoptosis and necrosis. However, SpHL-GEVPG:DOX at molar ratio of 1:1 showed lower induction of both apoptotic and necrotic pathways compared to free DOX and SpHL-DOX, suggesting that the mechanism of death involved may not be related to necrosis or apoptosis. Lastly, SpHL-GEVPG:DOX 1:1 showed a good storage stability for 90 d at 4 °C. Therefore, the results of the present work indicate the potential use of SpHL-GEVPG:DOX 1:1 as a new anticancer formulation.

Synergistic Effect of Drug Delivery System Combining DOX and V9302 on Gastric Cancer Cells**

Liposomes co-encapsulating doxorubicin and glucoevatromonoside derivative induce synergic cytotoxic response against breast cancer cell lines

Synergistic Effects of Antitumor Efficacy Via Mixed Nano-Size Micelles of Multifunctional Bletilla Striata Polysaccharide-Based Copolymer and D-α-tocopheryl Polyethylene Glycol Succinate.

Co-delivery of Doxorubicin and Arsenite with Reduction and Ph Dual-Sensitive Vesicle for Synergistic Cancer Therapy

Doxorubicin Combined with Betulinic Acid or Lonidamine in RGD Ligand-Targeted Ph-Sensitive Micellar System for Ovarian Cancer Treatment

Super-pH-Sensitive Mesoporous Silica Nanoparticle-Based Drug Delivery System for Effective Combination Cancer Therapy

Glycyrrhetinic Acid-Conjugated Polymeric Prodrug Micelles Co-Delivered with Doxorubicin As Combination Therapy Treatment for Liver Cancer.

Synergistic Combination Chemotherapy of Lung Cancer: Cisplatin and Doxorubicin Conjugated Prodrug Loaded, Glutathione and pH Sensitive Nanocarriers

Co-delivery Nanoparticles of Doxorubicin and Chloroquine for Improving the Anti-Cancer Effect in Vitro

Codelivery of Doxorubicin and Camptothecin by Dual-Responsive Unimolecular Micelle-Based Β-Cyclodextrin for Enhanced Chemotherapy.

Co-delivery of 2-Deoxyglucose and a glutamine metabolism inhibitor V9302 via a prodrug micellar formulation for synergistic targeting of metabolism in cancer

Co-Delivery of 2-Dg and V9302 Via a Prodrug Micellar Formulation for Synergistic Targeting of Metabolism in Cancer

Targeted delivery and stimulus-responsive release of anticancer drugs for efficient chemotherapy

Dual-pH Responsive Micelle Platform for Co-Delivery of Axitinib and Doxorubicin

Synergistic antitumor efficacy of doxorubicin and gambogic acid-encapsulated albumin nanocomposites

The design and synthesis of dextran-doxorubicin prodrug-based pH-sensitive drug delivery system for improving chemotherapy efficacy

Therapeutic Polymeric Nanomedicine: GSH-responsive Release Promotes Drug Release for Cancer Synergistic Chemotherapy.

Co-delivery Nanoparticles with Characteristics of Intracellular Precision Release Drugs for Overcoming Multidrug Resistance.

Acid/GSH Dual-Responsive Endosome Escape Dual Pro-drug Micelles Targeted Synergistic Treatment for A549/ADR

Co-Delivery of Doxorubicin and Anti-BCL-2 siRNA by pH-Responsive Polymeric Vector to Overcome Drug Resistance in In Vitro and In Vivo HepG2 Hepatoma Model.

Synergistic Cisplatin/Doxorubicin Combination Chemotherapy for Multidrug-Resistant Cancer Via Polymeric Nanogels Targeting Delivery.